Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma

• Published in: Cancer letters 2011-11, Vol.310 (2), p.181-187
• Main Authors: Ai, Zhilong, Pan, Hongtao, Suo, Tao, Lv, Chentao, Wang, Yueqi, Tong, Saixiong, Liu, Houbao
• Format: Article
• Language: English
• Subjects: AC133 Antigen; AKT; Antigens, CD - biosynthesis; Antigens, CD - genetics; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Apoptosis - physiology; arsenic; Arsenic trioxide; Arsenicals - pharmacology; Cancer; Cancer therapies; carcinoma; CD133; Cell culture; Cell Line, Tumor; chemotherapy; Down-Regulation - drug effects; drug resistance; Drug Resistance, Neoplasm; Flow cytometry; gall bladder; Gallbladder carcinoma; Gallbladder Neoplasms - drug therapy; Gallbladder Neoplasms - immunology; Gallbladder Neoplasms - pathology; Glycoproteins - biosynthesis; Glycoproteins - genetics; Hematology, Oncology and Palliative Medicine; Humans; Leukemia; Neoplastic Stem Cells - drug effects; Neoplastic Stem Cells - immunology; Neoplastic Stem Cells - pathology; Oxides - pharmacology; Peptides - genetics; Plasmids - genetics; Proto-Oncogene Proteins c-akt - metabolism; RNA, Messenger - biosynthesis; RNA, Messenger - genetics; Signal Transduction; Statistical analysis; stem cells; transcription (genetics); Transfection; Tumors
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2011.06.035

Highlights ► Resistance of CD133+ gallbladder carcinoma cells to cisplatin and adriamycin. ► CD133 regulates arsenic trioxide-induced cell apoptosis. ► Arsenic trioxide regulates CD133 expression at transcription level. ► CD133 regulates AKT signaling pathway.